Literature DB >> 8889715

In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum.

A Giacometti1, O Cirioni, G Scalise.   

Abstract

The anticryptosporidial activity of four macrolides alone and in combination with other antimicrobial agents was investigated against ten clinical isolates of Cryptosporidium parvum recovered from stools of AIDS patients. The susceptibility tests were performed by inoculation of the protozoa on to cell monolayers and determining the parasite count after 72 h incubation at 37 degrees C. The culture medium was supplemented with Dulbecco's modified Eagle's medium containing serial dilutions of azithromycin, clarithromycin, roxithromycin, spiramycin, alone or in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine. Most of the agents had an inhibitory effect on parasite growth, but only at high concentrations. No agent was able to inhibit parasite growth completely, even at the highest concentrations used. The more effective agents, azithromycin, clarithromycin, roxithromycin, minocycline and pyrimethamine, produced no more than a 13.1-27.8% reduction in oocyst count and no more than a 15.1-35.7% in schizont count. Positive interaction was clearly demonstrated when macrolides were tested in combination with minocycline or pyrimethamine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889715     DOI: 10.1093/jac/38.3.399

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  Novel paradigms for drug discovery: computational multitarget screening.

Authors:  Ekachai Jenwitheesuk; Jeremy A Horst; Kasey L Rivas; Wesley C Van Voorhis; Ram Samudrala
Journal:  Trends Pharmacol Sci       Date:  2008-01-10       Impact factor: 14.819

2.  [(1)N,(12)N]Bis(Ethyl)-cis-6,7-dehydrospermine: a new drug for treatment and prevention of Cryptosporidium parvum infection of mice deficient in T-cell receptor alpha.

Authors:  W R Waters; B Frydman; L J Marton; A Valasinas; V K Reddy; J A Harp; M J Wannemuehler; N Yarlett
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 3.  Artemisinin and its derivatives in treating protozoan infections beyond malaria.

Authors:  Cecilia Shi Ni Loo; Nelson Siu Kei Lam; Deying Yu; Xin-Zhuan Su; Fangli Lu
Journal:  Pharmacol Res       Date:  2016-11-17       Impact factor: 7.658

Review 4.  Targeting purine and pyrimidine metabolism in human apicomplexan parasites.

Authors:  John E Hyde
Journal:  Curr Drug Targets       Date:  2007-01       Impact factor: 3.465

5.  Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth.

Authors:  Kovi Bessoff; Adam Sateriale; K Kyungae Lee; Christopher D Huston
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

6.  Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models.

Authors:  C M Theodos; J K Griffiths; J D'Onfro; A Fairfield; S Tzipori
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

7.  Genetic screens reveal a central role for heme metabolism in artemisinin susceptibility.

Authors:  Clare R Harding; Saima M Sidik; Boryana Petrova; Nina F Gnädig; John Okombo; Alice L Herneisen; Kurt E Ward; Benedikt M Markus; Elizabeth A Boydston; David A Fidock; Sebastian Lourido
Journal:  Nat Commun       Date:  2020-09-23       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.